Processa Pharmaceuticals, Inc. (PCSA) AI Stock Analysis

Processa Pharmaceuticals, Inc., based in Hanover, Maryland, is a clinical-stage biopharmaceutical company advancing treatments for conditions lacking effective therapies. Its pipeline is led by PCS499, an oral tablet in Phase 2B clinical trials for necrobiosis lipoidica. The company is also developing PCS12852, a selective 5-HT4 receptor agonist in Phase 2A trials for gastroparesis and chronic constipation. In oncology, Processa is progressing PCS3117 in Phase 2B trials for pancreatic and non-small cell lung cancers, PCS6422 in Phase 1B trials for metastatic colorectal and breast cancers, and PCS11T for various cancer types.

Between FY2015 and FY2017, Processa experienced a revenue CAGR of -79.0%. Revenue stood at $113,425 in FY2015 and FY2016, with net income at -$3.4M in both years. In FY2017, revenue fell 95.6% to $5,000, while net income was -$1.9M alongside an operating margin of -36048.7% and a gross margin of -37.3%. For the trailing twelve months ended June 30, 2026, the company recorded $0 in revenue, a profit margin of 0.0%, an operating margin of 0.0%, and EPS of -$4.33.

As of June 30, 2026, Processa held cash and short-term investments of $196,325 against total assets of $2.1M. The current ratio was 0.87, and shareholders' equity was -$317,341, reflecting negative equity. In FY2025, cash deployment included capital expenditures of $5 and share buybacks of $10,404. Over the trailing five-year period, the share count increased by 8660.2%.

Processa carries a market capitalization of $4.7M and an enterprise value of -$257,456. The stock trades at a price-to-book multiple of 2.8x and an EV to revenue multiple of 68.3x. In comparison, the median of its US-listed Healthcare peers trades at a price-to-sales multiple of 4.1x and an EV to EBITDA multiple of 12.0x. Over the past year, PCSA shares fell 81.2%, while the S&P 500 rose 16.8%. Over five years, the stock dropped 100.0% compared to an 83.0% gain for the S&P 500.

Processa has a mean price target of $25.00, representing a 1379.3% premium compared to its last close of $1.69 on October 16, 2026. For the next fiscal year, 1 analyst projects revenue of $0, reflecting 0.0% growth, and an EPS estimate of -$3.75, representing an estimated EPS growth of 65.1%. Over the last four quarters, Processa beat EPS estimates in 3 quarters. The next earnings date is scheduled for November 5, 2026.

This page is an AI-written research summary of Processa Pharmaceuticals, Inc. (PCSA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PCSA income statement, PCSA balance sheet, PCSA key metrics, PCSA analyst forecast, PCSA chart. See the PCSA stock overview for the latest quote and news.